You will undergo screening to confirm if you meet the study requirements for mild to moderate Alzheimer’s Disease

Your thinking abilities will be tested using the MMSE test (a standard memory and thinking assessment). Your score should be between 12 and 22

You must be between 60 and 85 years old to participate

You need to have a caregiver who spends at least 10 hours per week with you and can attend all study visits

If you are currently taking memory medications (AChEIs and/or memantine), you must have been on a stable dose for at least 12 weeks

You will need to maintain this same dose throughout the study

The study will last 24 weeks (approximately 6 months)

You will receive either KarXT + KarX-EC capsules or placebo capsules (inactive treatment)

The medication will be taken by mouth

Your caregiver will help ensure you take the medication as prescribed

Your thinking abilities will be tested regularly using the ADAS-Cog11 test

Your daily activities will be assessed using the ADCS-ADL assessment

Your behavior will be evaluated using the NPI assessment

Regular health checks will include vital signs, heart tests (ECG), weight measurements, and laboratory tests

Any side effects or health changes will be monitored throughout the study

At week 24, final assessments will be conducted to measure changes in your thinking abilities and overall function

Your caregiver will provide information about changes in your daily activities and behavior